Clinical Trials Logo

Atrial Fibrillation clinical trials

View clinical trials related to Atrial Fibrillation.

Filter by:

NCT ID: NCT02344394 Withdrawn - Clinical trials for Persistent Atrial Fibrillation

Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone vs Hybrid Ablation With PVI Plus Catheter Ablation

Start date: September 2014
Phase: N/A
Study type: Interventional

The overall objective of the study is to compare and assess the clinical outcomes of the standard of care hybrid ablation using epicardial ablation in conjunction with endocardial PVI alone versus epicardial ablation in conjunction with endocardial ablation using PVI with additional RF ablation in a randomized, prospective population of patients with persistent AF of at least 6 months duration. All devices that are used are being utilized under the approved labeling of the devices.

NCT ID: NCT02309268 Withdrawn - Atrial Fibrillation Clinical Trials

Atrial Appendage Closure Prospective Observational Study

LARIAT
Start date: June 2012
Phase: N/A
Study type: Observational

The purpose of this research is to monitor how well patients do after surgery for treatment of left atrial appendage (LAA).

NCT ID: NCT02193321 Withdrawn - Atrial Fibrillation Clinical Trials

Safety and Efficacy Study of Amniotic Membrane Patch to Treat Postoperative Atrial Fibrillation

Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to to evaluate the rate of new onset postoperative atrial fibrillation in subjects receiving the amniotic membrane patch placed on the epicardial surface as compared to subjects who did not undergo epicardium intervention.

NCT ID: NCT02153424 Withdrawn - Clinical trials for Non-valvular Atrial Fibrillation (NVAF)

Early Post-marketing Study of Eliquis (Apixaban)

Start date: April 2014
Phase: N/A
Study type: Observational

The primary objective of the study is to identify and describe any suspected (AEs) in all patients with NVAF treated with Apixaban, as a request of the National Center of Pharmacovigilance (CNFV) in Mexico.

NCT ID: NCT02120560 Withdrawn - Atrial Fibrillation Clinical Trials

Anticoagulation in AF Ablation and Effects on Neurocognitive Function

Start date: July 2014
Phase: Phase 4
Study type: Interventional

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States, and treatment by AF ablation is quickly becoming the favored definitive therapy. Nonetheless, AF ablation comes with some risk, including bleeds related to vascular access and myocardial damage, as well as the rare incidence of clinical stroke from blood clots that travel from the heart to the brain, termed "cerebrothromboemboli." In fact, cerebrothromboemboli without any symptoms have been detected by special imaging procedures called brain magnetic resonance imaging (MRI) in as many as 22% of cases.(1-6) There remains clinical equipoise amongst experts regarding balancing the risks and benefits of continued versus interrupted blood thinning, or "anticoagulation" during AF ablation as they pertain to risk of bleed and cerebrothromboemboli prevention, respectively, and the potentially more subtle sequelae of these apparently silent cerebrothromboemboli remain unknown. In fact, both interruption and continuation of anticoagulation during AF ablation are the standard of care. The investigators will perform the first randomized trial of uninterrupted versus interrupted anticoagulation in patients undergoing AF ablation to determine if it mitigates neurologic injury. The objective of this research is to investigate the effect of continued anticoagulation for AF ablation on cerebrothromboemboli, and the neurocognitive sequelae of embolic lesions, which to this point are considered subclinical. The investigators hypothesize that continued anticoagulation will both reduce cerebrothromboemboli and mitigate any potential decline in neurocognitive function post-procedurally. The investigators also hypothesize that the incidence of cerebrothromboemboli (CTE) by MRI will mediate that difference.

NCT ID: NCT02099331 Withdrawn - Atrial Fibrillation Clinical Trials

Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin

DREAM
Start date: September 2014
Phase: Phase 2
Study type: Interventional

Atrial fibrillation is a common heart rhythm condition that can occur after cardiac surgery and has been associated with an increase in hospital length of stay, overall hospital costs, worsening clinical condition and higher rates of death. Newer research indicates that inflammation is a key contributor to atrial fibrillation in this setting. Melatonin is a naturally made hormone that is regarded as an extremely effective anti-inflammatory substance, with a very favorable safety profile. This clinical trial is being done to test the ability of melatonin to reduce the risk of developing atrial fibrillation after cardiac surgery. This is a research study where patients will be given either oral melatonin at 40 mg or placebo nightly prior to sleep. The study product will start approximately 2 days prior to the scheduled surgery date and will continue until the 3rd day after the operation. The remainder of the clinical care will remain the same. The investigators project that patients who receive melatonin will have a significant decrease in the occurrence of atrial fibrillation after surgery.

NCT ID: NCT02035163 Withdrawn - Atrial Fibrillation Clinical Trials

Atrial Fibrillation Prevention in Post Coronary Artery Bypass Graft Surgery With Cryoablation for Ganglionic Plexi

Start date: July 2012
Phase: N/A
Study type: Interventional

Atrial fibrillation after coronary artery bypass graft is a common complication. The investigators have thought that the mechanism of temporarily postoperative atrial fibrillation is closely related to the autonomic nervous system imbalance. In a last several years, cryoablation was substituted for atrial incision in many reports to simplify the maze procedure. However, there has been no comparative study to delineate the feasibility of the use of cryoablation.

NCT ID: NCT01962051 Withdrawn - Stroke Clinical Trials

AMPLATZER Cardiac Plug (ACP) Latin American Post Market Observational

ACP LA
Start date: October 2013
Phase:
Study type: Observational

The ACP device will be clinically evaluated through a prospective, open-label, nonrandomized, multi-center post market clinical study.

NCT ID: NCT01924377 Withdrawn - Atrial Fibrillation Clinical Trials

Characterization and Elimination of Mother Rotors

CENTRA-AF
Start date: May 28, 2013
Phase: N/A
Study type: Interventional

Recent clinical studies have shown that atrial fibrillation (AF) in humans might be sustained by localized sources called "mother rotors" which exhibit persistent, fast, and well organized activity during AF and play an important role in the generation and maintenance of the fibrillatory activity. In this study, investigators aim to identify the electrophysiological characteristics of mother rotors during atrial fibrillation in patients with paroxysmal and persistent AF and to test whether ablation of such patient-specific substrates might improve the acute and long-term success of conventional catheter ablation therapy.

NCT ID: NCT01917981 Withdrawn - Stroke Clinical Trials

Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation

Start date: September 2013
Phase: Phase 3
Study type: Interventional

This study aims to determine the sensitivity and specificity of a Personal Heart Rhythm Monitor in the detection of prolonged paroxysmal atrial fibrillation (defined as lasting more than 12 hours) against pre-existing implantable devices, seen to be the 'gold-standard' for arrhythmia detection.